JERUSALEM, June 16, 2015 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)
(http://www.oramed.com), a developer of oral drug delivery systems,
announced today that the Russian Federal Service for Intellectual
Property has granted the Company a patent for its invention, titled
"Methods and Compositions for Oral Administrations of
Exenatide."
About ORMD-0901 - Oral GLP-1
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that
stimulates the secretion of insulin from the pancreas. Exenatide, a
GLP-1 analog, is currently marketed in injectable form only, and is
indicated for treatment of type 2 diabetes. Exenatide induces
insulin release at increased glucose levels and causes a feeling of
satiety, which results in reduced food intake and weight loss.
Oramed's oral GLP-1 capsule, based on the Company's POD™
technology, could significantly increase compliance and become a
valuable tool in the treatment of diabetes.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs currently delivered via
injection. Established in 2006, Oramed's Protein Oral Delivery
(POD™) technology is based on over 30 years of research by top
scientists at Jerusalem's Hadassah
Medical Center. Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801). Having completed separate
Phase IIa clinical trials, the Company anticipates the initiation
of separate Phase IIb clinical trials, in patients with both type 1
and type 2 diabetes under an Investigational New Drug application
with the U.S. Food and Drug Administration. In addition the Company
is developing an oral GLP-1 analog capsule (ORMD-0901).
For more information, the content of which is not part of
this press release, please
visit http://www.oramed.com
Forward-looking statements: This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss the possibility that
Oramed's capsule could increase compliance and become a valuable
tool in the treatment of diabetes, when we discuss revolutionizing
the treatment of diabetes with our products, or when we discuss our
clinical trials. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the SEC.
Company Contact
Oramed Pharmaceuticals
Ariella Vaystooch
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com
SOURCE Oramed Pharmaceuticals Inc.